Thrombolysis is an effective treatment strategy for prosthetic valve thrombosis (PVT). Recombinant tissue-type plasminogen activator (rt-PA) is widely used as a thrombolytic agent. Infusion of rt-PA may trigger the production of anti-tissue plasminogen activator (tPA) antibodies (ATAs). We aimed to evaluate the possible relationship between ATA levels and PVT formation, and the role of baseline ATA levels on outcomes of thrombolytic therapy in patients with PVT.
Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial / M. Özkan, M. Kalçık, M.O. Gürsoy, L. Öcal, S. Griffini, S. Karakoyun, M. Yesin, S. Gündüz, M.A. Astarcıoğlu, E. Bayam, S. Cerşit, A.Ç. Aykan, M. Cugno. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS. - ISSN 1074-2484. - 21:4(2016 Dec 08), pp. 372-380. [10.1177/1074248415615236]
Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial
S. Griffini;M. CugnoUltimo
2016
Abstract
Thrombolysis is an effective treatment strategy for prosthetic valve thrombosis (PVT). Recombinant tissue-type plasminogen activator (rt-PA) is widely used as a thrombolytic agent. Infusion of rt-PA may trigger the production of anti-tissue plasminogen activator (tPA) antibodies (ATAs). We aimed to evaluate the possible relationship between ATA levels and PVT formation, and the role of baseline ATA levels on outcomes of thrombolytic therapy in patients with PVT.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
